Dr. Michelle Ghert was recently invited to present at the Harvard Combined Orthopaedic Residency Grand Rounds in Boston, Massachusetts. Her talk entitled “International Randomized Trials in Orthopaedic Oncology: Joining Forces and Shifting the Paradigm” focused on the need for higher level evidence in the field of Orthopaedic Oncology and the elements required to successfully implement randomized controlled trials, with PARITY showcased as the main example.
PARITY is a multi-center, blinded, randomized controlled trial, using a parallel two-arm design to investigate whether long term postoperative antibiotic regimens (5 days) will decrease the rate of infection among patients being surgically treated for a lower extremity bone tumor, when compared to short term postoperative antibiotics (24 hours). The trial has currently enrolled more than a quarter of the 100 patients in the pilot sample. She was joined in Boston by the PARITY Scientific Officer (Nathan Evaniew) and the PARITY Methods Center Research Coordinator (Marilyn Swinton) who met with site coordinators, pharmacists, nurses and surgeons at Boston Children’s Hospital and Beth Israel Deaconess Medical Center in preparation for opening these sites to enrolment for PARITY.